Metropolis Healthcare (METROPOLIS) Q4 25/26 earnings summary

Executive summary

• Achieved strong organic revenue growth of 13.7% for FY26, with total group revenue up 23.6% year-over-year to INR 1,646 crore, driven by robust demand, operational efficiency, and successful integration of acquisitions.

• EBITDA margin expanded to 25.9% organically and 24.4% at group level, supported by productivity, mix improvement, and integration synergies.

• Specialty and TruHealth segments delivered high double-digit growth, with Specialty contributing 37%-39% and TruHealth 18%-19% of revenue.

• Digital channels now contribute 25% of revenue, enhancing customer engagement and margin profile.

• Audited standalone and consolidated financial results for FY26 were approved with an unmodified audit opinion from statutory auditors.

Financial highlights

• FY26 group revenue rose 23.6%-24% YoY to INR 1,646 crore; organic revenue up 14% YoY to INR 1,510 crore.

• Group EBITDA grew 32% YoY to INR 401 crore; organic EBITDA up 29% YoY to INR 392 crore.

• PAT increased 31% YoY to INR 191 crore for the group; consolidated net profit for FY26: ₹19,118.20 lakhs.

• Q4 FY26 group revenue: INR 425 crore, up 23% YoY; EBITDA margin 25.4%.

• Standalone and consolidated EPS for FY26: ₹7.60 and ₹9.19, respectively.

Outlook and guidance

• Revenue CAGR guidance of 14%-15% over the next three years, driven by 8%-9% patient volume growth and 5% realization improvement.

• Targeting sustainable group EBITDA margin of 27%-28% in three years, with 125-150 bps improvement expected in the coming year.

• Labour Code changes implemented from April 1, 2026, with ongoing assessment of regulatory impact.

• Company continues to monitor tax litigation and regulatory developments.

• Expansion plans include 100 mini hubs and 1,500 new collection centers, aiming for a 35:1 lab-to-center ratio.